- €16.65m
- €68.67m
- €92.98m
- 38
- 79
- 15
- 36
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 3.66 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.16 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.16 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -30.4% | ||
Return on Equity | -32.19% | ||
Operating Margin | -35.54% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | €m | 34.23 | 153.9 | 382.53 | 196.59 | 92.98 | 123.6 | 142.2 | 24.4% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +408.87 | +2492.91 | +170.49 | -73.56 | n/a | n/a | +475 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). It operates through Fumouze Diagnostics and SR2B.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 1st, 2005
- Public Since
- March 21st, 2011
- No. of Employees
- 521
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 10,443,877
- Address
- 22 Boulevard Sebastien Brant, ILLKIRCH-GRAFFENSTADEN, 67400
- Web
- https://www.biosynex.com
- Phone
- +33 388787887
- Auditors
- Deloitte & Associes
Upcoming Events for ALBIO
Similar to ALBIO
AbL Diagnostics SA
Euronext - Paris
Affluent Medical SAS
Euronext - Paris
Alpha MOS SA
Euronext - Paris
Amplitude Surgical SA
Euronext - Paris
Aton SA
Euronext - Paris
FAQ
As of Today at 18:38 UTC, shares in Biosynex SA are trading at €1.59. This share price information is delayed by 15 minutes.
Shares in Biosynex SA last closed at €1.59 and the price had moved by -80.75% over the past 365 days. In terms of relative price strength the Biosynex SA share price has underperformed the FTSE Global All Cap Index by -82.61% over the past year.
The overall consensus recommendation for Biosynex SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiosynex SA does not currently pay a dividend.
Biosynex SA does not currently pay a dividend.
Biosynex SA does not currently pay a dividend.
To buy shares in Biosynex SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €1.59, shares in Biosynex SA had a market capitalisation of €16.65m.
Here are the trading details for Biosynex SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALBIO
Based on an overall assessment of its quality, value and momentum Biosynex SA is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biosynex SA is €12.60. That is 690.46% above the last closing price of €1.59.
Analysts covering Biosynex SA currently have a consensus Earnings Per Share (EPS) forecast of €0.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biosynex SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -61.37%.
As of the last closing price of €1.59, shares in Biosynex SA were trading -60.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biosynex SA PE ratio based on its reported earnings over the past 12 months is 3.66. The shares last closed at €1.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biosynex SA's management team is headed by:
- Larry Abensur - CEO
- Thomas Lamy - DCE
- Thierry Paper - DCE
- Elie Fraenckel - DRC